Terms: = Ovarian cancer AND TRB AND Treatment
3 results:
1. TCR CDR3-antigen chemical complementarity associated with poor ovarian cancer outcomes: A vestigial immune response to early cancer antigens?
Barker VR; Varkhedi M; Patel DN; Hsiang M; Chobrutskiy A; Chobrutskiy BI; Blanck G
Am J Reprod Immunol; 2023 Jan; 89(1):e13639. PubMed ID: 36317868
[TBL] [Abstract] [Full Text] [Related]
2. CD44-targeting for antitumor drug delivery: a new SN-38-hyaluronan bioconjugate for locoregional treatment of peritoneal carcinomatosis.
Serafino A; Zonfrillo M; Andreola F; Psaila R; Mercuri L; Moroni N; Renier D; Campisi M; Secchieri C; Pierimarchi P
Curr Cancer Drug Targets; 2011 Jun; 11(5):572-85. PubMed ID: 21486216
[TBL] [Abstract] [Full Text] [Related]
3. Expression of human tumor mucin-associated carbohydrate epitopes, including sialylated Tn, and localization of murine monoclonal antibodies CC49 and B72.3 in a syngeneic rat colon carcinoma model.
O'Boyle KP; Goya V; Zuckier LS; Chun S; Bhargava K
J Immunother Emphasis Tumor Immunol; 1994 Nov; 16(4):251-61. PubMed ID: 7533599
[TBL] [Abstract] [Full Text] [Related]
